Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis

被引：4
|
作者：
Stein, Eytan M. [1 ]
Latremouille-Viau, Dominick [2 ]
Joseph, George J. [3 ]
Shi, Sherry [2 ]
Guerin, Annie [2 ]
Wu, Eric Q. [4 ]
Bonifacio, Gaetano [3 ]
Cao, Xiting [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] Novartis Pharmaceut, E Hanover, NJ USA
[4] Anal Grp Inc, Boston, MA USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124878
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3495
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Injectable Hypomethylating Agents for Management of Myelodysplastic Syndromes: Patients' Perspectives on Treatment
    Zeidan, Amer M.
    Jayade, Sayeli
    Schmier, Jordana
    Botteman, Marc
    Hassan, Audrey
    Ruiters, Desiree
    Hill, Kala
    Joshi, Namita
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (03): : E185 - E198
  • [22] Evaluation of Infection in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A Systematic Review
    Yang, Jiayu
    Choi, Nora
    Mozessohn, Lee
    Sanford, David
    Paulson, Kristjan
    Houston, Donald S.
    Rimmer, Emily
    Lother, Sylvain
    Mendelson, Asher
    Garland, Allan
    Buckstein, Rena
    Hay, Annette E.
    Zarychanski, Ryan
    Houston, Brett L.
    BLOOD, 2022, 140 : 12317 - 12318
  • [23] Prognostic value of the SEER-Medicare myelodysplastic syndromes risk score for a contemporary cohort of patients with MDS.
    Afzal, Amber
    Fiala, Mark A.
    Jacoby, Meagan
    Walter, Matthew
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18762 - E18762
  • [24] Treatment patterns and outcomes among elderly patients with chronic myeloid leukemia: An analysis of linked SEER-Medicare data.
    Menzin, J
    Lang, K
    Earle, C
    Glendenning, A
    BLOOD, 2002, 100 (11) : 875A - 875A
  • [25] Patterns among follicular lymphoma patients in seer-medicare
    Danese, M.
    Gleeson, M.
    Reyes, C.
    Pao, M.
    Knopf, K.
    ANNALS OF ONCOLOGY, 2008, 19 : 176 - 177
  • [26] Use of Oral Hypomethylating Agents for the Treatment of Myelodysplastic Syndromes
    Venugopal, Sangeetha
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S73 - S76
  • [27] Venetoclax Combination with Hypomethylating Agents for Treatment of Myelodysplastic Syndromes
    Al Ali, Najla
    Sallman, David
    Nelson, Rebecca
    Talati, Chetasi
    Kuykendall, Andrew
    Sweet, Kendra
    Padron, Eric
    Lancet, Jeffrey
    List, Alan
    Komrokji, Rami
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S339 - S340
  • [28] Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes and Myeloid Leukemia
    Szmigielska-Kaplon, Anna
    Robak, Tadeusz
    CURRENT CANCER DRUG TARGETS, 2011, 11 (07) : 837 - 848
  • [29] Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes
    Cheng, Wendy Y.
    Satija, Ambika
    Cheung, Hoi Ching
    Hill, Kala
    Wert, Tim
    Laliberte, Francois
    Lefebvre, Patrick
    HEMATOLOGY, 2021, 26 (01) : 261 - 270
  • [30] Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
    Finelli, Carlo
    Follo, Matilde Y.
    Stanzani, Marta
    Parisi, Sarah
    Clissa, Cristina
    Mongiorgi, Sara
    Barraco, Marilena
    Cocco, Lucio
    CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (16) : 2349 - 2357
12345